Background: Animal studies indicate maternal folic acid intake alters offspring amino acids (AAs) and fatty acid profiles, affecting their long-term health. However, human data on specific folate metabolites remain limited. We explored their dynamic associations with neonatal AAs and acylcarnitines (ACs).
Methods: We conducted a prospective cohort study, involving 4130 singleton pregnant women and their neonates. Maternal total folate and related metabolites in red blood cell (RBC), including 5-methyltetrahydrofolate (5-MTHF), tetrahydrofolate (THF), 5-formyltetrahydrofolate (5-CHO-THF), and unmetabolized folic acid (UMFA), were measured in 6-17 (T1), 20-26 (T2), and 32-36 (T3) gestational weeks. Neonatal metabolites, including 11 AAs and 31 ACs, were routinely tested 72 h postpartum using heel blood samples. Linear regression and pathway analysis were used to evaluate associations between maternal folate metabolites with neonatal metabolic pathways.
Results: 5-MTHF and total folate levels significantly increased from T1 to T2 (p < 0.001), and stabilized from T2 to T3 (p > 0.05). THF and 5-CHO-THF levels showed a continuous upward trend (p < 0.001). Conversely, UMFA declined throughout pregnancy (p < 0.001). Total folate and 5-MTHF showed no significant correlations with neonatal metabolism. THF were associated with multiple neonatal metabolites, and the associations peaked in T1 and declined in T2 and T3. THF in T1 positively correlated with phenylalanine and tyrosine, involved in the phenylalanine and tyrosine metabolism. And it was positively associated with 7 ACs and negatively with 9 ACs, involved in the fatty acids β-oxidation. THF in T2 or T3 positively related to arginine, and negatively with citrulline, glycine, and ornithine, involved in the urea cycle and arginine and proline metabolism. 5-CHO-THF displayed similar and weaker impacts, correlated with fatty acids β-oxidation only in T1. UMFA exhibited different and weaker influence, related to the urea cycle, arginine and proline metabolism only in T1.
Conclusions: Although maternal total folate and 5-MTHF levels showed no significant association with neonatal metabolites, maternal certain folate metabolites, especially THF, exhibited trimester-specific associations with neonatal metabolic pathways, warranting clinical attention.
{"title":"Maternal red blood cell folate metabolites were dynamically associated with neonatal amino acids and acylcarnitines in heel blood: a prospective cohort study.","authors":"Ruihua Yang, Wei Zheng, Yixuan Lu, Yujie Zhang, Lirui Zhang, Xin Yan, Tengda Chen, Ziyu Wang, Xincong Shi, Yuanyuan Kong, Guanghui Li","doi":"10.1186/s12986-025-01064-2","DOIUrl":"10.1186/s12986-025-01064-2","url":null,"abstract":"<p><strong>Background: </strong>Animal studies indicate maternal folic acid intake alters offspring amino acids (AAs) and fatty acid profiles, affecting their long-term health. However, human data on specific folate metabolites remain limited. We explored their dynamic associations with neonatal AAs and acylcarnitines (ACs).</p><p><strong>Methods: </strong>We conducted a prospective cohort study, involving 4130 singleton pregnant women and their neonates. Maternal total folate and related metabolites in red blood cell (RBC), including 5-methyltetrahydrofolate (5-MTHF), tetrahydrofolate (THF), 5-formyltetrahydrofolate (5-CHO-THF), and unmetabolized folic acid (UMFA), were measured in 6-17 (T1), 20-26 (T2), and 32-36 (T3) gestational weeks. Neonatal metabolites, including 11 AAs and 31 ACs, were routinely tested 72 h postpartum using heel blood samples. Linear regression and pathway analysis were used to evaluate associations between maternal folate metabolites with neonatal metabolic pathways.</p><p><strong>Results: </strong>5-MTHF and total folate levels significantly increased from T1 to T2 (p < 0.001), and stabilized from T2 to T3 (p > 0.05). THF and 5-CHO-THF levels showed a continuous upward trend (p < 0.001). Conversely, UMFA declined throughout pregnancy (p < 0.001). Total folate and 5-MTHF showed no significant correlations with neonatal metabolism. THF were associated with multiple neonatal metabolites, and the associations peaked in T1 and declined in T2 and T3. THF in T1 positively correlated with phenylalanine and tyrosine, involved in the phenylalanine and tyrosine metabolism. And it was positively associated with 7 ACs and negatively with 9 ACs, involved in the fatty acids β-oxidation. THF in T2 or T3 positively related to arginine, and negatively with citrulline, glycine, and ornithine, involved in the urea cycle and arginine and proline metabolism. 5-CHO-THF displayed similar and weaker impacts, correlated with fatty acids β-oxidation only in T1. UMFA exhibited different and weaker influence, related to the urea cycle, arginine and proline metabolism only in T1.</p><p><strong>Conclusions: </strong>Although maternal total folate and 5-MTHF levels showed no significant association with neonatal metabolites, maternal certain folate metabolites, especially THF, exhibited trimester-specific associations with neonatal metabolic pathways, warranting clinical attention.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":" ","pages":"9"},"PeriodicalIF":4.1,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12809961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: Sancai Lianmei granules (SCLMG) have demonstrated efficacy in improving glucolipid metabolism disorder, insulin resistance, and oxidative stress markers in both diabetic patients and rodent models. However, there is limited data available regarding the effect of SCLMG on human Metabolic dysfunction-associated fatty liver disease (MAFLD). This research aims to assess the impact of SCLMG on MAFLD in individuals with diabetes.
Methods and research design: Sixty individuals diagnosed with type 2 diabetes mellitus (T2DM) and MAFLD were randomly allocated to one of two groups: the SCLMG group, which received standard treatment for T2DM along with SCLMG at a dose of 15 g three times daily, or the control group, which received standard treatment without SCLMG. The intervention lasted for 12 weeks. Alterations in liver fat content and liver sclerosis were evaluated using FibroScan. Secondary outcome measures included alterations in liver enzymes, fibrosis markers, advanced glycation end products AGEs, and metabolic parameters.
Results: When incorporated into the standard treatment regimen for MAFLD in diabetic patients, SCLMG exhibited an improvement in reducing hepatic steatosis (P = 0.048) while showing no substantial variations in liver stiffness (P = 0.762). Both the SCLMG and control groups revealed a substantial reduction in FibroScan readings at the end of the treatment period compared to baseline. The two groups exhibited substantial disparities in changes in liver enzymes (alanine aminotransferase (ALT) P = 0.018, aspartate aminotransferase (AST) P = 0.006, gamma-glutamyltranspeptidase (GGT) P < 0.001), skin autofluorescence (SAF) (P = 0.012), and metabolic parameters (P < 0.05). Nevertheless, there was a variation between the groups regarding serum procollagen III peptide (PIIIP) levels (P = 0.026), whereas changes in type Ⅳcollagen (CⅣ) (P = 0.265), hyaluronic acid (HA) (P = 0.199), laminin (LN) (P = 0.144), and high-density lipoprotein cholesterol (HDL-C) (P = 0.315) levels were not statistically significant.
Conclusions: SCLMG is beneficial in regulating glucolipid metabolism and liver function. To a certain extent, SCLMG can improve liver steatosis and shows a tendency towards reducing liver sclerosis. Therefore, SCLMG has a good effect on individuals with T2DM and MAFLD.
目的:三菜连梅颗粒(SCLMG)对糖尿病患者和啮齿类动物的糖脂代谢紊乱、胰岛素抵抗和氧化应激指标均有改善作用。然而,关于scmg对人类代谢功能障碍相关脂肪性肝病(MAFLD)的影响,现有的数据有限。本研究旨在评估scmg对糖尿病患者MAFLD的影响。方法与研究设计:将60例确诊为2型糖尿病(T2DM)合并MAFLD的患者随机分为两组:1组为scmg组,接受T2DM合并scmg的标准治疗,剂量为15 g,每日3次;2组为对照组,接受不含scmg的标准治疗。干预持续12周。肝脂肪含量的改变和肝硬化用纤维扫描评估。次要结局指标包括肝酶、纤维化标志物、晚期糖基化终产物AGEs和代谢参数的改变。结果:当纳入糖尿病患者MAFLD的标准治疗方案时,SCLMG在减少肝脏脂肪变性方面表现出改善(P = 0.048),而在肝脏僵硬方面没有显着变化(P = 0.762)。在治疗期结束时,与基线相比,SCLMG组和对照组的纤维扫描读数都有显著降低。两组肝脏酶(丙氨酸转氨酶(ALT) P = 0.018,天冬氨酸转氨酶(AST) P = 0.006, γ -谷氨酰转肽酶(GGT) P)的变化存在显著差异。结论:SCLMG对糖脂代谢和肝功能有调节作用。scmg可在一定程度上改善肝脂肪变性,并有减轻肝硬化的倾向。因此,scmg对T2DM和MAFLD患者有很好的疗效。试验注册:ChiCTR2000033099|| http://www.chictr.org.cn/ 2020年5月20日。注册细节:https://www.chictr.org.cn/hvshowprojectEN.html?id=34391&v=1.5。
{"title":"Effects of Sancai Lianmei Granules in type 2 diabetes patients with metabolic dysfunction-associated fatty liver disease: a randomized prospective open-label controlled trial.","authors":"Shengju Wang, Yuguo Xia, Xuke Han, Yang Gao, Xiaoran Zhang, Xingxing Lei, Xu Zhang, Qiu Chen","doi":"10.1186/s12986-025-00996-z","DOIUrl":"10.1186/s12986-025-00996-z","url":null,"abstract":"<p><strong>Objective: </strong>Sancai Lianmei granules (SCLMG) have demonstrated efficacy in improving glucolipid metabolism disorder, insulin resistance, and oxidative stress markers in both diabetic patients and rodent models. However, there is limited data available regarding the effect of SCLMG on human Metabolic dysfunction-associated fatty liver disease (MAFLD). This research aims to assess the impact of SCLMG on MAFLD in individuals with diabetes.</p><p><strong>Methods and research design: </strong>Sixty individuals diagnosed with type 2 diabetes mellitus (T2DM) and MAFLD were randomly allocated to one of two groups: the SCLMG group, which received standard treatment for T2DM along with SCLMG at a dose of 15 g three times daily, or the control group, which received standard treatment without SCLMG. The intervention lasted for 12 weeks. Alterations in liver fat content and liver sclerosis were evaluated using FibroScan. Secondary outcome measures included alterations in liver enzymes, fibrosis markers, advanced glycation end products AGEs, and metabolic parameters.</p><p><strong>Results: </strong>When incorporated into the standard treatment regimen for MAFLD in diabetic patients, SCLMG exhibited an improvement in reducing hepatic steatosis (P = 0.048) while showing no substantial variations in liver stiffness (P = 0.762). Both the SCLMG and control groups revealed a substantial reduction in FibroScan readings at the end of the treatment period compared to baseline. The two groups exhibited substantial disparities in changes in liver enzymes (alanine aminotransferase (ALT) P = 0.018, aspartate aminotransferase (AST) P = 0.006, gamma-glutamyltranspeptidase (GGT) P < 0.001), skin autofluorescence (SAF) (P = 0.012), and metabolic parameters (P < 0.05). Nevertheless, there was a variation between the groups regarding serum procollagen III peptide (PIIIP) levels (P = 0.026), whereas changes in type Ⅳcollagen (CⅣ) (P = 0.265), hyaluronic acid (HA) (P = 0.199), laminin (LN) (P = 0.144), and high-density lipoprotein cholesterol (HDL-C) (P = 0.315) levels were not statistically significant.</p><p><strong>Conclusions: </strong>SCLMG is beneficial in regulating glucolipid metabolism and liver function. To a certain extent, SCLMG can improve liver steatosis and shows a tendency towards reducing liver sclerosis. Therefore, SCLMG has a good effect on individuals with T2DM and MAFLD.</p><p><strong>Trial registration: </strong>ChiCTR2000033099|| http://www.chictr.org.cn/ 20 May 2020. REGISTRATION DETAILS AT: https://www.chictr.org.cn/hvshowprojectEN.html?id=34391&v=1.5.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":"22 1","pages":"153"},"PeriodicalIF":4.1,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12729198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-24DOI: 10.1186/s12986-025-01049-1
Chun Yang, Zeng Guo, Mengqing Ma, Shiyu Jin, Shuyi Zhang, Ling Xia, Longfeng Xia, Xianhe Lin
Background: Insulin resistance (IR) is a well-established risk factor for cardiovascular disease (CVD). The metabolic score for insulin resistance (METS-IR) is a novel surrogate marker for IR, yet the association between its long-term cumulative burden and incident CVD remains unexplored, particularly in the Chinese population.
Methods: This prospective study included 5,264 participants (mean age 58.50 years; 46.6% male) from the China Health and Retirement Longitudinal Study (CHARLS). Cumulative average METS-IR was calculated as the mean of measurements from 2011 (baseline) and 2015 (wave 3). Incident CVD events were ascertained via standardized questionnaires. Multivariable logistic regression and restricted cubic spline models were employed to assess associations.
Results: During a 4-year follow-up, 554 (10.5%) incident CVD cases occurred. After full adjustment, each SD increase in cumulative average METS-IR was associated with a 16.1% higher risk of total CVD (OR = 1.161, 95% CI: 1.050-1.282). A significant dose-response relationship was observed (P for trend = 0.003). Crucially, we found a striking organ-specific disparity: the highest quartile of cumulative METS-IR was strongly associated with a 19.8% increased risk of heart disease (OR = 1.509, 95% CI: 1.118-2.046) but not with stroke (OR = 0.902, 95% CI: 0.440-1.865). Subgroup analyses revealed that this association was particularly pronounced among males, normotensive individuals, and current smokers or drinkers.
Conclusions: Cumulative exposure to insulin resistance, quantified by METS-IR, is an independent predictor of CVD, especially heart disease, in middle-aged and older Chinese adults. Our findings highlight the clinical utility of longitudinal METS-IR assessment for early risk stratification and pinpoint specific high-risk populations for targeted preventive strategies.
{"title":"Differential associations of cumulative average metabolic score for insulin resistance with heart disease and stroke: a prospective cohort study of middle-aged and older Chinese adults.","authors":"Chun Yang, Zeng Guo, Mengqing Ma, Shiyu Jin, Shuyi Zhang, Ling Xia, Longfeng Xia, Xianhe Lin","doi":"10.1186/s12986-025-01049-1","DOIUrl":"10.1186/s12986-025-01049-1","url":null,"abstract":"<p><strong>Background: </strong>Insulin resistance (IR) is a well-established risk factor for cardiovascular disease (CVD). The metabolic score for insulin resistance (METS-IR) is a novel surrogate marker for IR, yet the association between its long-term cumulative burden and incident CVD remains unexplored, particularly in the Chinese population.</p><p><strong>Methods: </strong>This prospective study included 5,264 participants (mean age 58.50 years; 46.6% male) from the China Health and Retirement Longitudinal Study (CHARLS). Cumulative average METS-IR was calculated as the mean of measurements from 2011 (baseline) and 2015 (wave 3). Incident CVD events were ascertained via standardized questionnaires. Multivariable logistic regression and restricted cubic spline models were employed to assess associations.</p><p><strong>Results: </strong>During a 4-year follow-up, 554 (10.5%) incident CVD cases occurred. After full adjustment, each SD increase in cumulative average METS-IR was associated with a 16.1% higher risk of total CVD (OR = 1.161, 95% CI: 1.050-1.282). A significant dose-response relationship was observed (P for trend = 0.003). Crucially, we found a striking organ-specific disparity: the highest quartile of cumulative METS-IR was strongly associated with a 19.8% increased risk of heart disease (OR = 1.509, 95% CI: 1.118-2.046) but not with stroke (OR = 0.902, 95% CI: 0.440-1.865). Subgroup analyses revealed that this association was particularly pronounced among males, normotensive individuals, and current smokers or drinkers.</p><p><strong>Conclusions: </strong>Cumulative exposure to insulin resistance, quantified by METS-IR, is an independent predictor of CVD, especially heart disease, in middle-aged and older Chinese adults. Our findings highlight the clinical utility of longitudinal METS-IR assessment for early risk stratification and pinpoint specific high-risk populations for targeted preventive strategies.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":"22 1","pages":"154"},"PeriodicalIF":4.1,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12729148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145827591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-23DOI: 10.1186/s12986-025-00939-8
Georgina M Williams, Emily C Hoedt, Kerith Duncanson, Lay Gan, Emilia Prakoso, Nicholas J Talley, Eleanor J Beck
Background: Dietary therapy, specifically for weight loss, is currently considered first-line therapy for metabolic-associated steatotic liver disease (MASLD). However, increasing recognition of the role of the gut-liver axis in MASLD highlights potential for microbiota-modulating dietary therapy to improve outcomes. This study aimed to explore dietary variables relevant to gut microbiota in MASLD.
Methods: Twenty-five adults with MASLD and 25 healthy controls were recruited using a retrospective case-control design and characterised using 3-day dietary intake records, clinical markers, and shotgun metagenomic sequencing.
Results: MASLD participants consumed less dietary fibre (p = < 0.01), very long chain omega-3 fatty acids (p = 0.02), nuts and seeds (p = 0.03), whole grains (p < 0.01) and vegetables (p = 0.04). Participants with MASLD had lower abundance of Alistipes senegalensis (r=-0.01, p = 0.04), Coprococcus eutactus (r=-0.07, p = 0.006), Faecalibacterium (r=-0.02, p < 0.001), and higher abundance of Ruminococcus torques (r = 0.04, p = 0.02), and less expression of functional pathways associated with ethanol production, methionine, folate and branched-chain amino acid metabolism. Bacterial species and functional pathways more abundant in MASLD were positively associated with intake of added sugars and saturated fat, and negatively associated with unsaturated fatty acid and dietary fibre intake.
Conclusions: Microbiota characteristics differ between individuals with and without MASLD, and this is influenced by dietary intake. Future translation-focused research investigating dietary interventions and the gut-liver-axis in MASLD are warranted.
{"title":"Inverse associations between Mediterranean diet constituents and the gut microbiota in metabolic-associated steatotic liver disease (MASLD): a case-control study.","authors":"Georgina M Williams, Emily C Hoedt, Kerith Duncanson, Lay Gan, Emilia Prakoso, Nicholas J Talley, Eleanor J Beck","doi":"10.1186/s12986-025-00939-8","DOIUrl":"10.1186/s12986-025-00939-8","url":null,"abstract":"<p><strong>Background: </strong>Dietary therapy, specifically for weight loss, is currently considered first-line therapy for metabolic-associated steatotic liver disease (MASLD). However, increasing recognition of the role of the gut-liver axis in MASLD highlights potential for microbiota-modulating dietary therapy to improve outcomes. This study aimed to explore dietary variables relevant to gut microbiota in MASLD.</p><p><strong>Methods: </strong>Twenty-five adults with MASLD and 25 healthy controls were recruited using a retrospective case-control design and characterised using 3-day dietary intake records, clinical markers, and shotgun metagenomic sequencing.</p><p><strong>Results: </strong>MASLD participants consumed less dietary fibre (p = < 0.01), very long chain omega-3 fatty acids (p = 0.02), nuts and seeds (p = 0.03), whole grains (p < 0.01) and vegetables (p = 0.04). Participants with MASLD had lower abundance of Alistipes senegalensis (r=-0.01, p = 0.04), Coprococcus eutactus (r=-0.07, p = 0.006), Faecalibacterium (r=-0.02, p < 0.001), and higher abundance of Ruminococcus torques (r = 0.04, p = 0.02), and less expression of functional pathways associated with ethanol production, methionine, folate and branched-chain amino acid metabolism. Bacterial species and functional pathways more abundant in MASLD were positively associated with intake of added sugars and saturated fat, and negatively associated with unsaturated fatty acid and dietary fibre intake.</p><p><strong>Conclusions: </strong>Microbiota characteristics differ between individuals with and without MASLD, and this is influenced by dietary intake. Future translation-focused research investigating dietary interventions and the gut-liver-axis in MASLD are warranted.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":" ","pages":"8"},"PeriodicalIF":4.1,"publicationDate":"2025-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12809944/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-22DOI: 10.1186/s12986-025-01060-6
Duoyu Ma, Xinyi Cheng, Qing Fang, Shunyu Ni, Fan Wang, Pengfei Hu
Objective: Including dairy products in the diet may help reduce the risk of developing cardiovascular disease (CVD). Nevertheless, how various categories of dairy items influence CVD risk remains insufficiently explored. This study aimed to evaluate the associations between different types of dairy products, their intake frequency, fat content, and the risk of CVD, addressing existing research gaps.
Methods: Dairy intake data-including yogurt, cheese, and milk-were obtained from the Global Dietary Database, covering 185 countries between 1990 and 2018. Corresponding CVD burden metrics-including incidence, prevalence, and disability-adjusted life years (DALYs)-were extracted from the Global Burden of Disease study. These data were used to investigate how dairy intake relates to CVD burden globally. Additionally, individual-level data from 30,341 participants in the National Health and Nutrition Examination Survey (NHANES) were analyzed to evaluate the association between dairy product consumption and CVD risk. Finally, directed acyclic graph and causal mediation models were used to confirm whether inflammatory markers partially mediated the association between dairy consumption and CVD risk.
Results: Globally, individuals who consumed greater amounts of milk tended to have a lower risk of CVD. Individually, milk intake was found to be negatively associated with the risk of CVD, coronary heart disease (CHD), and heart attack (HA). Exploratory mediation analysis indicated that systemic inflammatory markers (SIRI), the monocyte-to-lymphocyte ratio (MLR), and the neutrophil-to-lymphocyte ratio (NLR) partially mediated the relationship between milk intake and CVD risk, contributing - 6.09%, -5.02%, and - 4.13% of the total association, respectively. Further analysis showed that individuals who reported drinking milk daily or at least weekly tended to have a lower risk of developing CVD than those who consumed it less than once per week.
Conclusion: Milk intake may offer protective effects against CVD, CHD, and HA, potentially through the mitigation of inflammation. The frequency of milk intake appears to be a key factor influencing CVD risk. These findings highlight the potential public health benefits of promoting regular milk intake as part of a balanced dietary pattern to help reduce the global burden of CVD.
{"title":"Dairy consumption and cardiovascular disease risk: a multi-level analysis with inflammatory biomarker mediation.","authors":"Duoyu Ma, Xinyi Cheng, Qing Fang, Shunyu Ni, Fan Wang, Pengfei Hu","doi":"10.1186/s12986-025-01060-6","DOIUrl":"10.1186/s12986-025-01060-6","url":null,"abstract":"<p><strong>Objective: </strong>Including dairy products in the diet may help reduce the risk of developing cardiovascular disease (CVD). Nevertheless, how various categories of dairy items influence CVD risk remains insufficiently explored. This study aimed to evaluate the associations between different types of dairy products, their intake frequency, fat content, and the risk of CVD, addressing existing research gaps.</p><p><strong>Methods: </strong>Dairy intake data-including yogurt, cheese, and milk-were obtained from the Global Dietary Database, covering 185 countries between 1990 and 2018. Corresponding CVD burden metrics-including incidence, prevalence, and disability-adjusted life years (DALYs)-were extracted from the Global Burden of Disease study. These data were used to investigate how dairy intake relates to CVD burden globally. Additionally, individual-level data from 30,341 participants in the National Health and Nutrition Examination Survey (NHANES) were analyzed to evaluate the association between dairy product consumption and CVD risk. Finally, directed acyclic graph and causal mediation models were used to confirm whether inflammatory markers partially mediated the association between dairy consumption and CVD risk.</p><p><strong>Results: </strong>Globally, individuals who consumed greater amounts of milk tended to have a lower risk of CVD. Individually, milk intake was found to be negatively associated with the risk of CVD, coronary heart disease (CHD), and heart attack (HA). Exploratory mediation analysis indicated that systemic inflammatory markers (SIRI), the monocyte-to-lymphocyte ratio (MLR), and the neutrophil-to-lymphocyte ratio (NLR) partially mediated the relationship between milk intake and CVD risk, contributing - 6.09%, -5.02%, and - 4.13% of the total association, respectively. Further analysis showed that individuals who reported drinking milk daily or at least weekly tended to have a lower risk of developing CVD than those who consumed it less than once per week.</p><p><strong>Conclusion: </strong>Milk intake may offer protective effects against CVD, CHD, and HA, potentially through the mitigation of inflammation. The frequency of milk intake appears to be a key factor influencing CVD risk. These findings highlight the potential public health benefits of promoting regular milk intake as part of a balanced dietary pattern to help reduce the global burden of CVD.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":" ","pages":"156"},"PeriodicalIF":4.1,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-21DOI: 10.1186/s12986-025-01068-y
Elyas Nattagh-Eshtivani, Hanieh Barghchi, Amir Hossein Mansouri, Pegah Rahbarinejd, Amin Mokari-Yamchi, Mehdi Barati, Mohammad Rashidmyvan, Ali Jafazadeh Esfehani, Alireza Mohammadzadeh, Zachry Clyton, Parisa Marabi, Saeedeh Talebi, Naseh Pahlavani
{"title":"The role of dietary factors in the prevention and management of inflammatory bowel disease: a comprehensive review.","authors":"Elyas Nattagh-Eshtivani, Hanieh Barghchi, Amir Hossein Mansouri, Pegah Rahbarinejd, Amin Mokari-Yamchi, Mehdi Barati, Mohammad Rashidmyvan, Ali Jafazadeh Esfehani, Alireza Mohammadzadeh, Zachry Clyton, Parisa Marabi, Saeedeh Talebi, Naseh Pahlavani","doi":"10.1186/s12986-025-01068-y","DOIUrl":"10.1186/s12986-025-01068-y","url":null,"abstract":"","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":" ","pages":"157"},"PeriodicalIF":4.1,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751218/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-21DOI: 10.1186/s12986-025-01046-4
Yanan Xu, Shoupeng Duan, Wenyuan Yin, Yi Yang, Xianlin Zhang, Jun Wang
{"title":"Machine learning-enhanced prediction model for atrial fibrillation development in patients with concurrent type 2 diabetes and obstructive sleep apnea syndrome: a comorbidity perspective.","authors":"Yanan Xu, Shoupeng Duan, Wenyuan Yin, Yi Yang, Xianlin Zhang, Jun Wang","doi":"10.1186/s12986-025-01046-4","DOIUrl":"10.1186/s12986-025-01046-4","url":null,"abstract":"","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":" ","pages":"158"},"PeriodicalIF":4.1,"publicationDate":"2025-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-20DOI: 10.1186/s12986-025-01069-x
Xi Luo, Weiwei Jin
Background and objective: The composite dietary antioxidant index (CDAI) is a tool to assess an individual's comprehensive dietary antioxidant intake profiles. This study aimed to explore the association between energy-adjusted composite dietary antioxidant index (E-CDAI) and sarcopenic obesity (SO).
Methods: Participants from the NHANES cohort (n = 4388) and the Tongde Hospital of Zhejiang Province cohort (n = 276) were enrolled in the present study. Logistic regression analyses were applied to explore the association between E-CDAI (both continuous and quintiles) and SO. Moreover, the mediating effect of inflammatory/nutritional indicators were evaluated to investigate the association between E-CDAI and SO.
Results: In the NHANES cohort, logistic regression demonstrated a significant inverse correlation between E-CDAI and SO (adjust odd ratio (OR)continuous =0.89, 95% CI = 0.81, 0.98, P = 0.041; adjust ORQ5vsQ1 =0.44, 95% CI = 0.29, 1.18, Ptrend =0.050) In the Chinese population cohort, an inverse correlation also existed between E-CDAI and SO (adjust ORcontinuous =0.72, 95% CI = 0.60, 0.87, P < 0.001; adjust ORQ5vsQ1 =0.30, 95% CI = 0.13, 0.74, Ptrend <0.001). Applying data from the NHANES cohort, the mediation analysis indicated that neutrophil-percentage-to-albumin ratio mediated 12.812% and C-reactive protein mediated 6.485% of the associations between E-CDAI and SO.
Conclusion: A decreased E-CDAI score is associated with the increased risk of SO in adults. The association appeared to be partially mediated through inflammatory/nutritional pathways, suggesting that the E-CDAI may serve as a valuable indicator for identification of individuals at risk for SO.
背景与目的:复合膳食抗氧化指数(CDAI)是一种评估个人膳食抗氧化剂综合摄入量的工具。本研究旨在探讨能量调节复合膳食抗氧化指数(E-CDAI)与肌肉减少性肥胖(SO)的关系。方法:来自NHANES队列(n = 4388)和浙江省同德医院队列(n = 276)的参与者纳入本研究。采用Logistic回归分析探讨E-CDAI(连续和五分位数)与SO之间的关系。此外,我们还评估了炎症/营养指标的介导作用,以研究E-CDAI与SO之间的关系。结果:在NHANES队列中,logistic回归显示E-CDAI与SO呈显著负相关(调整奇数比(OR)连续=0.89,95% CI = 0.81, 0.98, P = 0.041;在中国人群队列中,E-CDAI与SO之间也存在负相关(调整或连续=0.72,95% CI = 0.60, 0.87, P Q5vsQ1 =0.30, 95% CI = 0.13, 0.74, P趋势)结论:成人E-CDAI评分降低与SO风险增加相关。这种关联似乎部分是通过炎症/营养途径介导的,这表明E-CDAI可以作为识别SO风险个体的有价值指标。
{"title":"The association between composite dietary antioxidant index and sarcopenic obesity.","authors":"Xi Luo, Weiwei Jin","doi":"10.1186/s12986-025-01069-x","DOIUrl":"10.1186/s12986-025-01069-x","url":null,"abstract":"<p><strong>Background and objective: </strong>The composite dietary antioxidant index (CDAI) is a tool to assess an individual's comprehensive dietary antioxidant intake profiles. This study aimed to explore the association between energy-adjusted composite dietary antioxidant index (E-CDAI) and sarcopenic obesity (SO).</p><p><strong>Methods: </strong>Participants from the NHANES cohort (n = 4388) and the Tongde Hospital of Zhejiang Province cohort (n = 276) were enrolled in the present study. Logistic regression analyses were applied to explore the association between E-CDAI (both continuous and quintiles) and SO. Moreover, the mediating effect of inflammatory/nutritional indicators were evaluated to investigate the association between E-CDAI and SO.</p><p><strong>Results: </strong>In the NHANES cohort, logistic regression demonstrated a significant inverse correlation between E-CDAI and SO (adjust odd ratio (OR)<sub>continuous</sub> =0.89, 95% CI = 0.81, 0.98, P = 0.041; adjust OR<sub>Q5vsQ1</sub> =0.44, 95% CI = 0.29, 1.18, P<sub>trend</sub> =0.050) In the Chinese population cohort, an inverse correlation also existed between E-CDAI and SO (adjust OR<sub>continuous</sub> =0.72, 95% CI = 0.60, 0.87, P < 0.001; adjust OR<sub>Q5vsQ1</sub> =0.30, 95% CI = 0.13, 0.74, P<sub>trend</sub> <0.001). Applying data from the NHANES cohort, the mediation analysis indicated that neutrophil-percentage-to-albumin ratio mediated 12.812% and C-reactive protein mediated 6.485% of the associations between E-CDAI and SO.</p><p><strong>Conclusion: </strong>A decreased E-CDAI score is associated with the increased risk of SO in adults. The association appeared to be partially mediated through inflammatory/nutritional pathways, suggesting that the E-CDAI may serve as a valuable indicator for identification of individuals at risk for SO.</p>","PeriodicalId":19196,"journal":{"name":"Nutrition & Metabolism","volume":" ","pages":"155"},"PeriodicalIF":4.1,"publicationDate":"2025-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12751180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145800586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}